CD274 and neoplasm: In the recent molecular profiling of the CARACAS trial, there was significantly better OS (HR = 0.33, 95% CI, 0.13–0.81; p = 0.015) and PFS (HR = 0.48, 95% CI, 0.23–1.00; p = 0.015) in patients with high tumor mutational burden (TMB) and PD-L1 [69].